Pharmac Consultation
- admin82291
- Sep 18
- 1 min read
Proposal to fund a new brand of methylphenidate for ADHD
Pharmac is seeking feedback on a proposal to fund a new modified-release brand of methylphenidate - Methylphenidate Sandoz XR - to help ease ongoing supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD).
If approved, this brand would be funded from 1 December 2025.
We welcome your feedback. Consultation is open until 5 pm, Wednesday 1 October 2025.
Please send your feedback to consult@pharmac.govt.nz or use the online form linked in the consultation.
Ngā mihi,
Ashleigh Kleinsman (she/her) | Therapeutic Group Manager
___________________________________________________________________
Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
P: 0800 660 050 | www.pharmac.govt.nz